Hematopoiesis News Volume 13.10 | Mar 15 2022

    By
    Justin.choi
    -
    0
    33






    2022-03-15 | HN 13.10


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.10 – 15 March, 2022
    TOP STORY

    Lamin B1 Deletion in Myeloid Neoplasms Causes Nuclear Anomaly and Altered Hematopoietic Stem Cell Function

    Scientists showed that loss of nuclear lamin B1 encoded on chromosome 5q, which was frequently deleted in myeloid neoplasms, induced defects in nuclear morphology and human HSCs function associated with malignancy.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    PUBLICATIONSRanked by the impact factor of the journal

    Non-Canonical Function of AGO2 Augments T Cell Receptor Signaling in T Cell Prolymphocytic Leukemia

    A novel T cell receptor (TCR)-associated non-canonical function of AGO2 represented, in addition to TCL1A-mediated TCR signal augmentation, another enhancer mechanism of an important deregulated growth pathway in T cell prolymphocytic leukemia.
    [Cancer Research]

    Abstract

    Globin Vector Regulatory Elements Are Active in Early Hematopoietic Progenitor Cells

    The authors demonstrated that lentivirally encoded locus control region elements, in particular HS1 and HS2, could be activated in early hematopoietic cells including hematopoietic stem cells and myeloid progenitors.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Identification of the Global miR-130a Targetome Reveals a Role for TBL1XR1 in Hematopoietic Stem Cell Self-Renewal and t(8; 21) AML

    Investigators established that identification of the comprehensive miRNA targetome within primary cells enabled discovery of genes and molecular networks underpinning stemness properties of normal and leukemic cells.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Characterization of Disease-Propagating Stem Cells Responsible for Myeloproliferative Neoplasm-Blast Phase

    The authors showed that myeloproliferative neoplasm (MPN)-blast phase (BP) initiating cells originated from not only phenotypically identified hematopoietic stem cells but also lymphoid-myeloid progenitor cells which were each characterized by differences in MPN-BP initiating activity and self-renewal capacity.
    [JCI Insight]

    Abstract|
    Full Artcile

    CaMKK2 Knockout Bone Marrow Cells Collected/Processed in Low Oxygen (Physioxia) Suggests CaMKK2 as a Hematopoietic Stem to Progenitor Differentiation Fate Determinant

    Researchers considered physioxia collection/processing a more relevant way to assess HSC/HPC numbers and function, as the cells remained in an oxygen tension closer physiologic conditions.
    [Stem Cell Reviews and Reports]

    AbstractGraphical Abstract

    CEACAM1 Is a Novel Culture-Compatible Surface Marker of Expanded Long-Term Reconstituting Hematopoietic Stem Cells

    Investigators identified CEACAM1 as a novel culture-compatible surface marker of ex vivo expanded long-term reconstituting-HSCs that further refined the immuno-phenotype of the cells.
    [Blood Advances]

    Abstract

    Comprehensive Phenotyping of Hematopoietic Stem and Progenitor Cells in the Human Fetal Liver

    Scientists presented a comprehensive overview of traditional and more recently described markers for phenotyping HSCs and their downstream progeny.
    [Cytometry Part A]

    Abstract

    Deficiency of SARS-CoV-2 T-Cell Responses after Vaccination in Long-Term Allo-HSCT Survivors Translates into Abated Humoral Immunity

    Recipients of hematopoietic stem cell transplantation showed weaker immune responses to COVID-19 vaccines than healthy controls
    [Blood Advances]

    Abstract

    PERK Reprograms Hematopoietic Progenitor Cells to Direct Tumor-Promoting Myelopoiesis in the Spleen

    Scientist found that PKR-like endoplasmic reticulum kinase (PERK) mediated hematopoietic stem/progenitor cell reprogramming into committed MDSC precursors in the spleen via PERK–ATF4–C/EBPβ signaling.
    [Journal of Experimental Medicine]

    Abstract


    Dr. Daniel Dever, describes a CRISPR-Cas9-based protocol for gene editing hematopoietic stem cells in this on-demand webinar.
    REVIEWS

    Revisiting Hematopoiesis: Applications of the Bulk and Single-Cell Transcriptomics Dissecting Transcriptional Heterogeneity in Hematopoietic Stem Cells

    The authors discuss the recent findings and computational methods used to unravel the new HSC model revise over the classical model.
    [Briefings in Functional Genomics]

    Abstract

    INDUSTRY AND POLICY NEWS

    ExCellThera Announces First Patient Treated in Phase I/II Trial of ECT-001 Cell Therapy for Pediatric Patients with High Risk Blood Cancer

    ExCellThera Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of ECT-001 for the treatment of pediatric and young adults with high risk myeloid malignancies.
    [ExCellThera, Inc. (GlobeNewswire, Inc.)]

    Press Release

    FEATURED EVENT

    AACR Annual Meeting 2022

    April 8 – 13, 2022
    New Orleans, Louisiana, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Associate – Hematology/Oncology

    University of Illinois Chicago – Chicago, Illinois, United States

    Senior Staff Scientist – Primary Cells

    Wellcome Sanger Institute – Cambridge, United Kingdom

    Full Project Scientist – Division of Cardiovascular Medicine

    The University of California, Davis – Davis, California, United States

    Researcher – Cancer Biology

    BC Cancer Research Institute – BC Cancer Research Institute

    Postdoctoral Scientist – Cellular Immunology/T Cell Therapy

    TU Dresden – Dresden, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter